LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Начало・Списък с акции・Compugen Ltd

Compugen Ltd

Затворен

2.71 -0.73

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.69

Максимум

2.77

Ключови измерители
By Trading Economics
Приходи	64M 57M
Продажби	65M 67M
P/E Средно за сектора	7.526 49.701
Марж на печалбата	84.425
Служители	75
EBITDA	63M 56M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+71.06% upside

Дивиденти
By Dow Jones
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	59M 270M
Предишно отваряне	3.44
Предишно затваряне	2.71

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.25 / 1.48 Подкрепа & съпротива

Compugen Ltd Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

19.05.2026 г., 20:36 ч. UTC

Придобивния, сливания и поглъщания

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19.05.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19.05.2026 г., 23:28 ч. UTC

Пазарно говорене

Печалби

Global Forex and Fixed Income Roundup: Market Talk

19.05.2026 г., 23:28 ч. UTC

Пазарно говорене

Печалби

F&P Healthcare's Outlook Key for Investors -- Market Talk

19.05.2026 г., 23:10 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

19.05.2026 г., 23:10 ч. UTC

Пазарно говорене

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19.05.2026 г., 22:02 ч. UTC

Печалби

ZTO Express (Cayman): Di Xu to Resign From Board

19.05.2026 г., 22:01 ч. UTC

Печалби

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19.05.2026 г., 22:01 ч. UTC

Печалби

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19.05.2026 г., 22:00 ч. UTC

Печалби

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19.05.2026 г., 21:37 ч. UTC

Печалби

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19.05.2026 г., 21:31 ч. UTC

Придобивния, сливания и поглъщания

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19.05.2026 г., 21:01 ч. UTC

Печалби

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19.05.2026 г., 20:58 ч. UTC

Печалби

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19.05.2026 г., 20:46 ч. UTC

Горещи акции

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19.05.2026 г., 20:43 ч. UTC

Пазарно говорене

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19.05.2026 г., 20:34 ч. UTC

Печалби

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19.05.2026 г., 20:32 ч. UTC

Печалби

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19.05.2026 г., 20:32 ч. UTC

Печалби

James Hardie Industries 4Q EPS 5c >JHX

19.05.2026 г., 20:32 ч. UTC

Печалби

James Hardie Industries 4Q Sales $1.4B >JHX

19.05.2026 г., 20:21 ч. UTC

Придобивния, сливания и поглъщания

Analog Devices to Buy Empower Semiconductor for $1.5B

19.05.2026 г., 20:18 ч. UTC

Пазарно говорене

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19.05.2026 г., 20:13 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

19.05.2026 г., 20:13 ч. UTC

Пазарно говорене

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19.05.2026 г., 20:03 ч. UTC

Придобивния, сливания и поглъщания

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19.05.2026 г., 20:03 ч. UTC

Придобивния, сливания и поглъщания

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19.05.2026 г., 20:02 ч. UTC

Придобивния, сливания и поглъщания

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19.05.2026 г., 20:02 ч. UTC

Придобивния, сливания и поглъщания

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19.05.2026 г., 19:23 ч. UTC

Пазарно говорене

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Compugen Ltd Прогноза

Ценова цел

By TipRanks

71.06% нагоре

12-месечна прогноза

Среден 4.67 USD 71.06%

Висок 6 USD

Нисък 4 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Compugen Ltd през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на Compugen Ltd през последните 3 месеца.

Техническа оценка

By Trading Central

1.25 / 1.48Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.